Motley Bio
Motley Bio provides multiomic profiling to enable early disease detection and accelerate biological discovery. The company combines genome, epigenome, and proteome measurements with AI-driven analytics to identify disease signals and biomarkers. It operates as a multiomic technology provider serving researchers and diagnostic developers, leveraging laboratory assays and machine learning models. Motley Bio targets biological discovery and diagnostics markets by offering integrated multiomic data and analytics for biomarker development and early-detection workflows.
Motley Bio
Motley Bio provides multiomic profiling to enable early disease detection and accelerate biological discovery. The company combines genome, epigenome, and proteome measurements with AI-driven analytics to identify disease signals and biomarkers. It operates as a multiomic technology provider serving researchers and diagnostic developers, leveraging laboratory assays and machine learning models. Motley Bio targets biological discovery and diagnostics markets by offering integrated multiomic data and analytics for biomarker development and early-detection workflows.
TL;DR
Sector: Biotechnology — AI-driven multiomics
Headquarters: San Mateo, California
Stage / Funding: Pre-Seed (investor: Plug and Play)
Product focus: Integrated genome, epigenome, and proteome profiling with ML analytics
Company Overview
Problem Domain
Early disease detection and biological discovery via multiomic measurement and AI analysis.
Industry
Biotechnology
Funding Track Record
Round listed on public profiles; amount not disclosed.
Investor Signal
“Plug and Play participation in pre-seed round”